Concurrent chemoradiotherapy with carboplatin and uracil-ftegafur in patients with stage two (T2 N0 M0) squamous cell carcinoma of the glottic larynx

Journal of Laryngology and Otology

Volumn 120, Issue 6, 2006, Pages 478-481

  Taguchi, T ^a   Tsukuda, M ^a   Mikami, Y ^a   Horiuchi, C ^a   Ishitoya, J I ^b   Katori, H ^b  

^a YOKOHAMA CITY UNIVERSITY   (Japan)

^b YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

Author keywords

1 UFT; Carboplatin; Carcinoma; Drug Therapy; Laryngeal Neoplasms; Radiotherapy

Indexed keywords

CARBOPLATIN; UFT; ANTINEOPLASTIC AGENT; TEGAFUR; URACIL;

ADULT; AGED; AREA UNDER THE CURVE; ARTICLE; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; HUMAN; LARYNX; LARYNX CARCINOMA; LIVER DYSFUNCTION; LIVER TOXICITY; MALE; MUCOSA INFLAMMATION; MULTIMODALITY CANCER THERAPY; NEUTROPENIA; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PRESERVATION; SKIN TOXICITY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; THERAPY EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; ADJUVANT CHEMOTHERAPY; CLINICAL TRIAL; DISEASE FREE SURVIVAL; DRUG ADMINISTRATION; GLOTTIS; LARYNX TUMOR; MIDDLE AGED; PHASE 2 CLINICAL TRIAL; RADIATION DOSE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, SQUAMOUS CELL; CHEMOTHERAPY, ADJUVANT; COMBINED MODALITY THERAPY; DISEASE-FREE SURVIVAL; DRUG ADMINISTRATION SCHEDULE; FEMALE; GLOTTIS; HUMANS; LARYNGEAL NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; RADIOTHERAPY DOSAGE; TEGAFUR; URACIL;

EID: 33750112678     PISSN: 00222151     EISSN: 17485460     Source Type: Journal    
DOI: 10.1017/S0022215106000880     Document Type: Article

References (27)

1. Howell-Burke D, Peters LJ, Goepfert H, Oswald MJ. T2 glottic cancer. Recurrence, salvage, and survival after definitive radiotherapy. Arch Otolaryngol Head Neck Surg 1990;116:830-5
2. Inoue T, Ikeda H, Teshima T, Murayama S. Prognostic factor of telecobalt therapy for early glottic carcinoma. Cancer 1992;70:2797-801
3. Le QT, Fu KK, Kroll S, Ryu JK, Quivey JM, Meyler TS et al. Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma. Int J Radiat Oncol Biol Phys 1997;39:115-26
4. Mendenhall WM, Amdur RJ, Morris CG, Hinerman RW. T1-T2N0 squamous cell carcinoma of the glottic larynx treated with radiation therapy. J Clin Oncol 2001;19: 4029-36
5. Warde P, O'Sullivan B, Bristow RG, Panzarella T, Keane TJ, Gullane PJ et al. T1/T2 glottic cancer managed by external beam radiotherapy: the influence of pretreatment hemoglobin on local control. Int J Radiat Oncol Biol Phys 1998;41:347-53
6. 2 laser. Acta Otolaryngol Suppl 1997;527:155-9
7. 2 laser excision for tis, T1, and T2 glottic carcinomas: cure rate and prognostic factors. Otolaryngol Head Neck Surg 2000;123: 124-31
8. Giovanni A, Guelfucci B, Gras R, Yu P, Zanaret M. Partial frontolateral laryngectomy with epiglottic reconstruction for management of early-stage glottic carcinoma. Laryngoscope 2001;111:663-8
9. Crampette L, Garrel R, Gardiner Q, Maurice N, Mondain M, Makeieff M et al. Modified subtotal laryngectomy with cricohyoidoepiglottopexy - long term results in 81 patients. Head Neck 1999;21:95-103
10. 2-laser treatment of recurrent glottic carcinoma. Head Neck 2001;23:177-80
11. Nibu K, Kamata S, Kawabata K, Nakamizo M, Nigauri T, Hoki K. Partial laryngectomy in the treatment of radiation-failure of early glottic carcinoma. Head Neck 1997;19: 116-20
12. Delsupehe KG, Zink I, Lejaegere M, Bastian RW. Voice quality after narrow-margin laser cordectomy compared with laryngeal irradiation. Otolaryngol Head Neck Surg 1999;121:528-33
13. McGuirt WF, Blalock D, Koufman JA, Feehs RS, Hilliard AJ, Greven K et al. Comparative voice results after laser resection or irradiation of T1 vocal cord carcinoma. Arch Otolaryngol Head Neck Surg 1994;120:951-5
14. Rydell R, Schalen L, Fex S, Elner A. Voice evaluation before and after laser excision vs. radiotherapy of T1A glottic carcinoma. Acta Otolaryngol 1995;115:560-5
15. Hirano M, Kurita S, Matsuoka H. Vocal function following hemilaryngectomy. Ann Otol Rhinol Laryngol 1987;96: 586-9
16. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE et al. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol 1989;7:1748-56
17. Eisenberger M, Hornedo J, Silva H, Donehower R, Spaulding M, Van Echo D. Carboplatin (NSC-241-240): an active platinum analog for the treatment of squamous-cell carcinoma of the head and neck. J Clin Oncol 1986;4: 1506-9
18. de Andres Basauri L, Lopez Pousa A, Alba E, Sampedro F. Carboplatin, an active drug in advanced head and neck cancer. Cancer Treat Rep 1986;70:1173-6
19. Douple EB, Richmond RC, O'Hara JA, Coughlin CT. Carboplatin as a potentiator of radiation therapy. Cancer Treat Rev 1985;12(suppl A):111-24
20. Harland SJ, Newell DR, Siddik ZH, Chadwick R, Calvert AH, Harrap KR. Pharmacokinetics of cis-diammine-1,1-cyclobutane dicarboxylate platinum(II) in patients with normal and impaired renal function. Cancer Res 1984;44:1693-7
21. Byfield JE, Calabro-Jones P, Klisak I, Kulhanian F. Pharmacologic requirements for obtaining sensitization of human tumor cells in vitro to combined 5-fluorouracil or ftorafur and X rays. Int J Radiat Oncol Biol Phys 1982;8: 1923-33
22. Smalley SR, Kimler BF, Evans RG. 5-Fluorouracil modulation of radiosensitivity in cultured human carcinoma cells. Int J Radiat Oncol Biol Phys 1991;20:207-11
23. Taguchi T, Ikeda Y, Mikami Y, Kawai S, Arai Y, Mochimatsu I et al. Combined radiotherapy and chemotherapy with carboplatin and UFT for head and neck squamous cell carcinoma. Anticancer Res 2003;23:713-17
24. Garden AS, Forster K, Wong PF, Morrison WH, Schechter NR, Ang KK. Results of radiotherapy for T2N0 glottic carcinoma: does the "2" stand for twice-daily treatment? Int J Radiat Oncol Biol Phys 2003;55:322-8
25. Nishimura Y, Nagata Y, Okajima K, Mitsumori M, Hiraoka M, Masunaga S et al. Radiation therapy for T1,2 glottic carcinoma: impact of overall treatment time on local control. Radiother Oncol 1996;40:225-32
26. Fein DA, Mendenhall WM, Parsons JT, Million RR. T1-T2 squamous cell carcinoma of the glottic larynx treated with radiotherapy: a multivariate analysis of variables potentially influencing local control. Int J Radiat Oncol Biol Phys 1993;25:605-11
27. Fein DA, Lee WR, Hanlon AL, Ridge JA, Langer CJ, Curran WJ Jr et al. Pretreatment hemoglobin level influences local control and survival of T1-T2 squamous cell carcinomas of the glottic larynx. J Clin Oncol 1995;13: 2077-83